tbuckley/cabot-search huggingface dataset:
Bioinspired Redwood‐Like Scaffolds Coordinated by In Situ‐Generated Silica‐Containing Hybrid Nanocoatings Promote Angiogenesis and Osteogenesis both In Vitro and In Vivo
Authors: Minhao Wu, Feixiang Chen, Ping Wu, Zhiqiang Yang, Sheng Zhang, Lingfei Xiao, Zhouming Deng, Chong Zhang, Yun Chen, Lin Cai
Journal: Advanced Healthcare Materials (2021)

Abstract Inspired by natural redwood and bone, a biomimetic strategy is presented to develop a highly bioactive redwood‐like nanocomposite via radial freeze casting of biocompatible hydrogels followed by the in situ coprecipitation of a Si‐containing CaP hybrid nanocoating (SCPN). The engineered material displays radially aligned macrochannels and a porous network structure similar to those of natural redwood. In addition to acting as a mechanical reinforcement, introducing SCPNs into the weak redwood‐like scaffold yields not only a nanoroughened surface topography, a low swelling ratio, retarded enzymatic degradation, and enhanced protein absorption abilities but also the sustained sequential release of Si and Ca ions, thereby providing essential biophysical and biochemical cues for effective bone regeneration. Benefiting from the redwood‐like structures and bioactive SCPNs, the biomimetic materials create a favorable microenvironment for promoting the initial adhesion, spreading, proliferation, and migration of bone marrow‐derived mesenchymal stem cells and human umbilical vein endothelial cells. Furthermore, the in vitro and in vivo data showed that the biocompatible redwood‐like scaffold with precipitated SCPN can synergistically promote osteogenesis and angiogenesis in their aligned direction. Collectively, this work presents a novel bioinspired redwood‐like material with multifunctional properties that provides new insight into bone defect repair.
1283P Predicting the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) by combining clinical and radiomic features
Authors: F. Tohidinezhad, A. Traverso, I. Zhovannik, A. Romita, L.E.L. Hendriks, A-M.C. Dingemans, J.G. Aerts, G. Bootsma, J.F. Vansteenkiste, S. Hashemi, E.F.F. Smit, H. Gietema, D. De Ruysscher
Journal: Annals of Oncology (2021)
946P Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)
Authors: T-Q. Zhang, M-X. Zuo, Z-J. Geng, Z-L. Huang, J-B. Li, P-H. Wu, Y-K. Gu
Journal: Annals of Oncology (2021)
1435TiP Adjuvant immunotherapy for resected esophageal squamous cell carcinoma with high risk of recurrence (AIRES): A multicenter, open-label, randomized, controlled phase III trial
Authors: X. Kang, J. Xu, R. Zhang, Y. Song, Z. Wang, B. Zhang, X. Chen, Q. Zheng, Y. Li, J. Qin, J. Huang, Y. Li, J. He
Journal: Annals of Oncology (2021)
943P Long-term outcome of the oldest-old patients (85 years or older) underwent proton beam therapy for hepatocellular carcinoma
Authors: T. Iizumi, T. Okumura, K. Maruo, K. Baba, M. Murakami, S. Shimizu, T. Saito, M. Nakajima, H. Makishima, H. Numajiri, M. Mizumoto, K. Nakai, H. Sakurai
Journal: Annals of Oncology (2021)
Machine learning–driven identification of early-life air toxic combinations associated with childhood asthma outcomes
Authors: Yan-Chak Li, Hsiao-Hsien Leon Hsu, Yoojin Chun, Po-Hsiang Chiu, Zoe Arditi, Luz Claudio, Gaurav Pandey, Supinda Bunyavanich
Journal: Journal of Clinical Investigation (2021)

Air pollution is a well-known contributor to asthma. Air toxics are hazardous air pollutants that cause or may cause serious health effects. Although individual air toxics have been associated with asthma, only a limited number of studies have specifically examined combinations of air toxics associated with the disease. We geocoded air toxic levels from the US National Air Toxics Assessment (NATA) to residential locations for participants of our AiRway in Asthma (ARIA) study. We then applied Data-driven ExposurE Profile extraction (DEEP), a machine learning–based method, to discover combinations of early-life air toxics associated with current use of daily asthma controller medication, lifetime emergency department visit for asthma, and lifetime overnight hospitalization for asthma. We discovered 20 multi–air toxic combinations and 18 single air toxics associated with at least 1 outcome. The multi–air toxic combinations included those containing acrylic acid, ethylidene dichloride, and hydroquinone, and they were significantly associated with asthma outcomes. Several air toxic members of the combinations would not have been identified by single air toxic analyses, supporting the use of machine learning–based methods designed to detect combinatorial effects. Our findings provide knowledge about air toxic combinations associated with childhood asthma.
706P Real-world study assessing physician rationale for initiating first-line (1L) immuno-oncology (IO) therapy for patients with advanced urothelial cancer (aUC)
Authors: M. Ajmera, J. Chang, A. Hitchens, M. Kearney, E. Esterberg, R. Kim, J. Cappelleri, G. Devgan, N. Costa, S. Candrilli
Journal: Annals of Oncology (2021)
Advances in acute myeloid leukemia
Authors: Laura F Newell, Rachel J Cook
Journal: BMJ (2021)

ABSTRACT Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis and disease progression have led to novel therapies for AML. Ongoing research and clinical trials are actively seeking to personalize therapy by identifying molecular targets, discovering patient specific and disease specific risk factors, and identifying effective combinations of modalities and drugs. This review focuses on important updates in diagnostic and disease classifications that reflect new understanding of the biology of AML, its mutational heterogeneity, some important genetic and environmental risk factors, and new treatment options including cytotoxic chemotherapy, novel targeted agents, and cellular therapies.
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Authors: E. Gabriela Chiorean, Katherine A. Guthrie, Philip A. Philip, Elizabeth M. Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S. Noel, Jennifer M. Suga, Ignacio Garrido-Laguna, Dana Backlund Cardin, Marc R. Radke, Mai Duong, Shay Bellasea, Andrew M. Lowy, Howard S. Hochster
Journal: Clinical Cancer Research (2021)

PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment with veliparib and mFOLFIRI versus FOLFIRI (control) for metastatic pancreatic cancer.
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma
Authors: Anne C. Wilke, Carmen Doebele, Alena Zindel, Kwang Seok Lee, Sara A. Rieke, Michele Ceribelli, Federico Comoglio, James D. Phelan, James Q. Wang, Yana Pikman, Dominique Jahn, Björn Häupl, Constanze Schneider, Sebastian Scheich, Frances A. Tosto, Hanibal Bohnenberger, Philipp Stauder, Frank Schnütgen, Mikolaj Slabicki, Zana A. Coulibaly, Sebastian Wolf, Kamil Bojarczuk, Björn Chapuy, Christian H. Brandts, Philipp Stroebel, Caroline A. Lewis, Michael Engelke, Xincheng Xu, Hahn Kim, Thanh Hung Dang, Roland Schmitz, Daniel J. Hodson, Kimberly Stegmaier, Henning Urlaub, Hubert Serve, Clemens A. Schmitt, Fernando Kreuz, Gero Knittel, Joshua D. Rabinowitz, Hans Christian Reinhardt, Matthew G. Vander Heiden, Craig Thomas, Louis M. Staudt, Thorsten Zenz, Thomas Oellerich
Journal: Blood (2021)
Introduction to the Theme “New Insights, Strategies, and Therapeutics for Common Diseases”
Authors: Paul A. Insel, Terrence F. Blaschke, Susan G. Amara, Urs A. Meyer
Journal: The Annual Review of Pharmacology and Toxicology (2021)

The reviews in Volume 62 of the Annual Review of Pharmacology and Toxicology (ARPT) cover a diverse range of topics. A theme that encompasses many of these reviews is their relevance to common diseases and disorders, including type 2 diabetes, heart failure, cancer, tuberculosis, Alzheimer's disease, neurodegenerative disorders, and Down syndrome. Other reviews highlight important aspects of therapeutics, including placebos and patient-centric approaches to drug formulation. The reviews with this thematic focus, as well as other reviews in this volume, emphasize new mechanistic insights, experimental and therapeutic strategies, and novel insights regarding topics in the disciplines of pharmacology and toxicology. As the editors of ARPT, we believe that these reviews help advance those disciplines and, even more importantly, have the potential to improve the health care of the world's population.
687P NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
Authors: L. Carril Ajuria, M. Naigeon, C. Dalban, A. Desnoyer, N. Rioux-Leclercq, C. Sautès-Fridman, M. Meylan, Y. Vano, B. Beuselinck, S. Chouaib, C. de Oliveira, F. Tantot, B. Escudier, L. Albiges, N. Chaput
Journal: Annals of Oncology (2021)
310P Substantial reduction in the percentage of metastatic breast cancer (MBC) which is HER-2 positive (HER-2+) over two decades: Sequential cohort analysis from the 1000 patient HER-2 study
Authors: J.J. Berenguer-Pina, C.M. Quinn, G. Gullo, D. Skrobo, C. Buckley, J.M. Walshe, D. Fennelly, M. Higgins, J. Ballot, D. Mccartan, N. Walsh, J.P. Crown
Journal: Annals of Oncology (2021)
207P Outcomes of patients with triple-negative breast cancer following neoadjuvant chemotherapy with anthracycline and taxane-based regimens plus carboplatin
Authors: B.F. Vaca-Cartagena, A. Becerril-Gaitan, A. Aranda-Gutierrez, A.S. Ferrigno, M. Roman-Zamudio, M.I. Torres-Leal, M.A. Acosta-Sandoval, F.A. Gonzalez-Mondellini, H.M. Diaz-Perez, S. Cardona-Huerta, R. Ortiz-López, C. Villarreal-Garza
Journal: Annals of Oncology (2021)
173P What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis
Authors: B.Y. Aktas, R.F. Degirmenciler, C.D. Durmaz, H. Taban, D.C. Guven, G. Guner, H.C. Yildirim, M. Demir, N. Kertmen, Z. Arık, O. Dizdar, S. Aksoy
Journal: Annals of Oncology (2021)
181P Pegylated liposomal doxorubicin (PLD) combined with docetaxel and trastuzumab in neoadjuvant treatment for HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial
Authors: Z. Song, H. Wang, Q. Yang, Y. Li, Y. Qi, E. Zhao, X. Kong, C. Yang
Journal: Annals of Oncology (2021)
A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression
Authors: Shuhang Liang, Hongrui Guo, Kun Ma, Xianying Li, Dehai Wu, Yiqi Wang, Wei Wang, Shugeng Zhang, Yifeng Cui, Yufeng Liu, Linmao Sun, Bo Zhang, Mengyang Xin, Ning Zhang, Huanran Zhou, Yao Liu, Jiabei Wang, Lianxin Liu
Journal: Cancer Research (2021)

Abstract As a member of the phospholipase family, phospholipase C beta 1 (PLCB1) is involved in phospholipid hydrolysis and is frequently upregulated in human cancer. However, little is known about the role of PLCB1 in cholangiocarcinoma (CCA). In this study, we uncover a role for PLCB1 in CCA progression and identify the underlying mechanisms. Both human CCA tissues and CCA cell lines expressed high levels of PLCB1. PLCB1 promoted tumor development and growth in various CCA mouse models, including transposon-based tumorigenesis models. PLCB1 activated PI3K/AKT signaling to induce CCA cells to undergo epithelial-to-mesenchymal transition (EMT). Mechanistically, PABPC1 interacted with PLCB1 and PI3K to amplify PLCB1-mediated EMT via PI3K/AKT/GSK3β/Snail signaling. Ectopic PLCB1 induced resistance to treatment with gemcitabine combined with cisplatin, which could be reversed by the AKT inhibitor MK2206. PLCB1 expression was regulated by miR-26b-5p through direct interaction with PLCB1 3′UTR. Collectively, these data identify a PLCB1–PI3K–AKT signaling axis vital for CCA development and EMT, suggesting that AKT can be used as a therapeutic target to overcome chemotherapy resistance in CCA patients with high PLCB1 expression. Significance: PLCB1 functions as an oncogenic driver in cholangiocarcinoma development that confers an actionable therapeutic vulnerability to AKT inhibition.
Outcomes of COVID-19 patients treated with noninvasive respiratory support outside-ICU setting: a Portuguese reality
Authors: L. Rodrigues Santos, R. Gonçalves Lopes, A.S. Rocha, M.D. Martins, T.C. Guimarães, M. Meireles, H. Vilaça, A. Castro, M. Mesquita
Journal: Pulmonology (2021)
645TiP TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
Authors: N. Agarwal, A.A. Azad, J. Mateo, N.D. Shore, J. Chakrabarti, H-C. Chen, S. Lanzalone, A. Niyazov, F. Saad
Journal: Annals of Oncology (2021)
Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
Authors: B Paiva, M-B Vídriales, L Rosiñol, J Martínez-López, M-V Mateos, E M Ocio, M-Á Montalbán, L Cordón, N C Gutiérrez, L Corchete, A Oriol, M-J Terol, M-A Echeveste, R De Paz, F De Arriba, L Palomera, J de la Rubia, J Díaz-Mediavilla, M Granell, A Gorosquieta, A Alegre, A Orfao, J-J Lahuerta, J Bladé, J F San Miguel
Journal: Leukemia (2013)
1034TiP ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma
Authors: R.D. Carvajal, J.S. Weber, A.Z. Dudek, J. Grewal, I. Mehmi, O. Hamid, Y. Du, M. Desai, Y. Wang, L. Sun, J. Rege, M.R. Middleton
Journal: Annals of Oncology (2021)
732P Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
Authors: J. Chen, W. Wei, L. Zheng, H. Li, Y. Feng, T. Wan, Q. Huang, G. Liu, H. Tu, J. Qiu, X. Jiang, Y. Xiong, M. Zheng, J. Li, H. Huang, L. Song, J. Liu, Y. Zhang
Journal: Annals of Oncology (2021)
A modified approach for endoscopic ultrasound-guided management of disconnected pancreatic duct syndrome via drainage of a communicating collection
Authors: Bachir Ghandour, Venkata S. Akshintala, Michael Bejjani, Daniel Szvarca, Mouen A. Khashab
Journal: Endoscopy (2021)

Endoscopic ultrasound (EUS)-guided pancreaticogastrostomy to drain the viable upstream pancreas in patients with disconnected pancreatic duct syndrome is technically challenging [1]. Here, we present a modified EUS-guided pancreaticogastrostomy via drainage of a fluid collection in communication with the duct disruption ([Video 1]).
276P Dalpiciclib, a novel CDK4/6 inhibitor, combined with pyrotinib for HER2+ advanced breast cancer: Interim results of a phase II trial
Authors: M. Yan, L. Niu, H. Lv, M. Zhang, S. Zhao, Y. Feng, J. Wang, H. Sun, None Z. Liu, H. Li
Journal: Annals of Oncology (2021)
Long time frames to detect the impact of changing COVID-19 measures, Canada, March to July 2020
Authors: Jessica E Stockdale, Renny Doig, Joosung Min, Nicola Mulberry, Liangliang Wang, Lloyd T Elliott, Caroline Colijn
Journal: Eurosurveillance (2021)

BackgroundMany countries have implemented population-wide interventions to control COVID-19, with varying extent and success. Many jurisdictions have moved to relax measures, while others have intensified efforts to reduce transmission.AimWe aimed to determine the time frame between a population-level change in COVID-19 measures and its impact on the number of cases.MethodsWe examined how long it takes for there to be a substantial difference between the number of cases that occur following a change in COVID-19 physical distancing measures and those that would have occurred at baseline. We then examined how long it takes to observe this difference, given delays and noise in reported cases. We used a susceptible-exposed-infectious-removed (SEIR)-type model and publicly available data from British Columbia, Canada, collected between March and July 2020.ResultsIt takes 10 days or more before we expect a substantial difference in the number of cases following a change in COVID-19 control measures, but 20-26 days to detect the impact of the change in reported data. The time frames are longer for smaller changes in control measures and are impacted by testing and reporting processes, with delays reaching ≥ 30 days.ConclusionThe time until a change in control measures has an observed impact is longer than the mean incubation period of COVID-19 and the commonly used 14-day time period. Policymakers and practitioners should consider this when assessing the impact of policy changes. Rapid, consistent and real-time COVID-19 surveillance is important to minimise these time frames.
1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment
Authors: E.A. Basak, N.S. Vermeer, K.D. Joode, D.P. Hurkmans, D.E.M. Velthuis, E. Oomen-de Hoop, M.W.J. Schreurs, S. Bins, C. van der Leest, A. Joosse, S.L. Koolen, R. Debets, A.A.M. van der Veldt, J.G. Aerts, R.H. Mathijssen
Journal: Annals of Oncology (2021)
Death of an offspring and parental risk of ischemic heart diseases: A population-based cohort study
Authors: Dang Wei, Imre Janszky, Fang Fang, Hua Chen, Rickard Ljung, Jiangwei Sun, Jiong Li, Krisztina D. László
Journal: PLoS Medicine (2021)

Background The death of a child is an extreme life event with potentially long-term health consequences. Knowledge about its association with ischemic heart diseases (IHDs) and acute myocardial infarction (AMI), however, is very limited. We investigated whether the death of an offspring is associated with the risk of IHD and AMI. Methods and findings We studied parents of live-born children recorded in the Danish (1973 to 2016) and the Swedish (1973 to 2014) Medical Birth Registers ( n = 6,711,952; mean age at baseline 31 years, 53% women). We retrieved information on exposure, outcomes, and covariates by linking individual-level information from several nationwide registers. We analyzed the abovementioned associations using Poisson regression. A total of 126,522 (1.9%) parents lost at least 1 child during the study period. Bereaved parents had a higher risk of IHD and AMI than the nonbereaved [incidence rate ratios (IRRs) (95% confidence intervals (CIs)): 1.20 (1.18 to 1.23), P &lt; 0.001 and 1.21 (1.17 to 1.25), P &lt; 0.001, respectively]. The association was present not only in case of losses due to CVD or other natural causes, but also in case of unnatural deaths. The AMI risk was highest in the first week after the loss [IRR (95% CI): 3.67 (2.08 to 6.46), P &lt; 0.001], but a 20% to 40% increased risk was observed throughout the whole follow-up period. Study limitations include the possibility of residual confounding by socioeconomic, lifestyle, or health-related factors and the potentially limited generalizability of our findings outside Scandinavia. Conclusions The death of an offspring was associated with an increased risk of IHD and AMI. The finding that the association was present also in case of losses due to unnatural causes, which are less likely to be confounded by cardiovascular risk factors clustering in families, suggests that stress-related mechanisms may also contribute to the observed associations.
Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei’s Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783–92
Authors: Keiichiro Mori, Manuela Schmidinger, Shin Egawa, Kilian M. Gust, Shahrokh F. Shariat
Journal: European Urology (2021)
733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study
Authors: G. Freyer, A. Floquet, O. Tredan, C. Langlois-Jacques, F. Selle, C. Abdeddaim, A. Leary, C. Dubot, M. Fabbro, L. Gladieff, C. Sajous
Journal: Annals of Oncology (2021)
A respiratory pandemic should focus the mind on tobacco control
Authors: Anthony A Laverty, Christopher Millett
Journal: Thorax (2021)

The idea that tobacco smoking may protect against COVID-19 was always an improbable one. Both wreak terrible tolls on human lives; as of 13th July 2021, COVID-19 has killed an estimated 4 million people while tobacco smoking kills 8 million people every year.1 2 Yet some early evidence appeared to indicate that smoking tobacco was linked to a reduced risk of COVID-19 infection and death. This finding unsurprisingly generated substantial interest among researchers, the medical profession and the public.3

The paper by Clift et al 4 in this issue advances our understanding of the links between tobacco smoking and COVID-19 by combining a range of relevant data to employ two separate analytic approaches. Together, these analyses suggest a causal role for tobacco smoking in COVID-19 severity. The authors linked data from UK Biobank with primary care records, COVID-19 testing data, hospital admissions and death certificates to perform both observational and Mendelian randomisation analyses. COVID-19 testing data were available only up until August 2020, meaning that data on confirmed infections were concentrated in hospital settings. The observational analyses did not find that current smokers were more likely to have confirmed COVID-19 infection, but they were more likely to be admitted to hospital and to die from the disease. For example, in models adjusting for age and sex, current smokers were more likely than never smokers to be admitted to hospital …